Search

Displaying results 1851 - 1860 of 10000 in total
  1. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Glucarpidase

    go.drugbank.com/drugs/DB08898
    ApprovedInvestigational

    In 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … It prevents methotrexate toxicity in patients with renal dysfunction who are undergoing high-dose methotrexate treatment, as it provides an alternative non-renal pathway for methotrexate elimination.

    Categories: Detoxifying Agents for Antineoplastic Treatment
  3. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    in combination with [DB09296], [DB09297], and [DB00503] for genotype 1b and with [DB00811] for genotype 1a of Hepatitis C [L852]. … Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label].

    Mixtures: Viekira XRCategories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    For the 2024-2025 season, an updated formulation was approved for use in Canada and the US to target the Omicron KP.2 subvariant.[L51404,L40074] … [L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older.

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.

  6. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century. … [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet.

    Categories: Agents used to treat hypothyroidism
  7. Target

    SPARC

    go.drugbank.com/bio_entities/BE0002145
    TargetHumans

    Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites;...

    Synonyms: Secreted protein acidic and rich in cysteine
  8. Target

    Neurotrophic factor BDNF precursor form

    go.drugbank.com/bio_entities/BE0003394
    TargetHumans

    Participates in axonal growth, pathfinding and in the modulation of dendritic growth and morphology. … Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS.

    Polypeptides: Neurotrophic factor BDNF precursor form
  9. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    the use of baricitinib for the treatment of COVID-19 in May 2022. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Chlorthalidone

    go.drugbank.com/drugs/DB00310
    ApprovedInvestigational

    Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. … In addition to its antihypertensive effects, chlorthalidone has also been shown to decrease platelet aggregation and vascular permeability, as well as promote angiogenesis in vitro, which is thought to

    Mixtures: ATENOLOL CO RATIO 100/25MGCategories: Antihypertensive Agents Indicated for Hypertension, Non Potassium Sparing Diuretics